Stock Analysis on Net
Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Biogen Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Current portion of notes payable — 999,800 999,500 999,100 998,800 — — — — — 1,501,800 1,495,800 1,495,300 — — — — — 3,300 3,200 573,200 559,900 561,500
Taxes payable 237,300 284,900 317,300 174,700 234,200 230,900 143,100 142,000 119,400 576,700 310,000 71,400 125,600 427,200 238,500 63,500 254,100 223,000 231,900 68,200 121,300 52,600 70,000
Accounts payable 383,200 434,800 398,700 589,200 427,900 375,300 430,400 454,900 398,400 383,900 389,000 530,800 382,200 377,100 378,000 370,500 342,300 295,700 345,800 395,500 298,700 330,300 316,400
Liabilities held for sale — — — — — — — — — — — — — 88,600 97,200 — — — — — — — —
Accrued expense and other 3,305,900 3,298,500 2,231,100 2,535,200 2,550,700 2,741,000 2,592,300 3,145,300 3,286,200 2,486,500 2,437,800 2,765,800 2,429,100 2,318,000 2,435,000 2,861,200 2,578,500 2,633,700 2,571,100 2,901,300 2,455,200 2,436,900 2,044,600
Current liabilities 3,926,400 5,018,000 3,946,600 4,298,200 4,211,600 3,347,200 3,165,800 3,742,200 3,804,000 3,447,100 4,638,600 4,863,800 4,432,200 3,210,900 3,148,700 3,295,200 3,174,900 3,152,400 3,152,100 3,368,200 3,448,400 3,379,700 2,992,500
Notes payable, excluding current portion 6,279,200 6,277,400 6,275,700 6,274,000 6,272,300 7,269,200 7,267,200 7,426,200 7,425,000 7,423,800 4,459,900 4,459,000 4,458,200 5,948,500 5,943,200 5,936,500 5,931,100 5,928,400 5,929,400 5,935,000 5,938,300 5,954,000 5,952,700
Deferred tax liability 328,900 480,600 571,200 694,500 774,700 918,900 966,700 1,032,800 1,123,400 1,461,500 2,722,800 2,810,800 2,820,400 2,400,600 1,741,700 1,636,200 1,114,600 1,160,800 1,331,100 122,600 120,700 100,800 94,500
Long-term operating lease liabilities 354,800 274,200 312,300 330,400 348,200 363,900 380,000 402,000 409,100 414,800 403,700 412,700 410,500 423,000 436,100 — — — — — — — —
Other long-term liabilities 1,198,100 1,167,800 1,287,900 1,320,500 1,318,200 1,356,400 1,411,800 1,329,600 1,428,100 1,475,400 1,357,300 1,348,900 1,370,900 1,355,800 1,353,800 1,389,400 1,511,800 1,457,600 1,640,000 1,628,700 716,900 750,900 688,800
Long-term liabilities 8,161,000 8,200,000 8,447,100 8,619,400 8,713,400 9,908,400 10,025,700 10,190,600 10,385,600 10,775,500 8,943,700 9,031,400 9,060,000 10,127,900 9,474,800 8,962,100 8,557,500 8,546,800 8,900,500 7,686,300 6,775,900 6,805,700 6,736,000
Total liabilities 12,087,400 13,218,000 12,393,700 12,917,600 12,925,000 13,255,600 13,191,500 13,932,800 14,189,600 14,222,600 13,582,300 13,895,200 13,492,200 13,338,800 12,623,500 12,257,300 11,732,400 11,699,200 12,052,600 11,054,500 10,224,300 10,185,400 9,728,500
Preferred stock, par value $0.001 per share — — — — — — — — — — — — — — — — — — — — — — —
Common stock, par value $0.0005 per share 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Additional paid-in capital — — 119,000 68,200 — — — — — — 100 — — — — — 47,800 — — 97,800 59,200 19,300 —
Accumulated other comprehensive loss (163,600) (110,400) (115,200) (106,700) (136,600) (171,800) (174,300) (299,000) (225,500) (181,000) (149,300) (135,200) (92,300) (252,900) (219,800) (240,400) (248,300) (261,600) (303,900) (318,400) (329,400) (338,800) (325,200)
Retained earnings 15,916,100 14,959,900 14,215,500 13,911,700 13,543,500 13,900,700 13,833,500 13,976,300 13,961,000 14,466,700 15,673,100 16,455,400 17,065,200 16,182,800 17,026,700 16,257,000 16,944,100 15,499,500 17,334,600 15,810,400 16,107,700 14,881,700 14,781,200
Treasury stock, at cost (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100) (2,977,100)
Total Biogen Inc. shareholders’ equity 12,775,500 11,872,500 11,242,300 10,896,200 10,429,900 10,751,900 10,682,200 10,700,300 10,758,500 11,308,700 12,546,900 13,343,200 13,995,900 12,952,900 13,829,900 13,039,600 13,766,600 12,260,900 14,053,700 12,612,800 12,860,500 11,585,200 11,479,000
Noncontrolling interests (8,700) (9,100) (21,600) 63,500 451,800 462,900 (19,000) (14,200) (14,000) (19,500) (10,000) (4,100) (4,100) (4,100) (7,900) (8,000) (6,800) (7,200) (16,200) (14,700) (11,600) (11,600) (11,600)
Total equity 12,766,800 11,863,400 11,220,700 10,959,700 10,881,700 11,214,800 10,663,200 10,686,100 10,744,500 11,289,200 12,536,900 13,339,100 13,991,800 12,948,800 13,822,000 13,031,600 13,759,800 12,253,700 14,037,500 12,598,100 12,848,900 11,573,600 11,467,400
Total liabilities and equity 24,854,200 25,081,400 23,614,400 23,877,300 23,806,700 24,470,400 23,854,700 24,618,900 24,934,100 25,511,800 26,119,200 27,234,300 27,484,000 26,287,600 26,445,500 25,288,900 25,492,200 23,952,900 26,090,100 23,652,600 23,073,200 21,759,000 21,195,900

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Biogen Inc. current liabilities increased from Q1 2022 to Q2 2022 but then decreased significantly from Q2 2022 to Q3 2022.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Biogen Inc. long-term liabilities decreased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Biogen Inc. total liabilities increased from Q1 2022 to Q2 2022 but then decreased significantly from Q2 2022 to Q3 2022.
Total Biogen Inc. shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Biogen Inc. total Biogen Inc. shareholders’ equity increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.